BioLineRX (BLRX)

• Market cap: $16.6M
• 1 day: -3.34%
• 5 days: -5.53%
• 1 month: -1.83%
• 3 months: -14.93%
• 6 months: 16.77%
• Year to date: -63.21%
• 1 year: -84.83%
• 5 years: -94.66%
• 10 years: -99.64%
• Sector: Healthcare
• Industry: Biotechnology

About: BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Employees: 28

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

979% more capital invested

Capital invested by funds: $28K [Q1] → $302K (+$274K) [Q2]

928% more call options, than puts

Call options by funds: $596K | Put options by funds: $58K

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

45% more funds holding

Funds holding: 11 [Q1] → 16 (+5) [Q2]

1.55% more ownership

Funds ownership: 0% [Q1] → 1.55% (+1.55%) [Q2]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3